Dihydroergotoxine mesylates, commonly known as ergoloid mesylates, has an FDA-labeled indication for use in the symptomatic therapy of age-related dementia, being employed in individuals over 60 years of age who manifest signs and symptoms of an idiopathic decline in mental capacity. Those who respond are thought to be ones suffering from some process related to aging or have some underlying condition of dementia, such as primary progressive dementia, Alzheimer's dementia, senile onset dementia, or multi-infarct dementia. The mechanism of action of dihydroergotoxine (ergoloid) mesylates in geriatric senility has not been determined.
Am J Pharm Educ. 2006 Oct 15; 70(5): 98.
Although the drug has been in use for several decades (under the brand names Hydergine, Hydergina, Gerimal, Niloric, Redizork, Alkergot, Cicanol, Redergin, Hydrine and others) it's not known how or why the drug has its apparently beneficial effects in some patients.
It's used to treat mood, behaviour, and other problems caused by changes in the brain due to(or multiple small strokes).
It's now thought that its effects may be due to alterations of neuro-transmission within neural synapses, rather than because of its tendency to increase blood flow, as was once assumed.
Ideas for new topics, and suggested additions / corrections for old ones, are always welcome.
If you have skills or interests in a particular field, and have suggestions for Wikenigma, get in touch !
Or, if you'd like to become a regular contributor . . . request a login password. Registered users can edit the entire content of the site, and also create new pages.
( The 'Notes for contributors' section in the main menu has further information and guidelines etc.)
You are currently viewing an auto-translated version of Wikenigma
Please be aware that no automatic translation engines are 100% accurate, and so the auto-translated content will very probably feature errors and omissions.
Nevertheless, Wikenigma hopes that the translated content will help to attract a wider global audience.